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Fruticin (amorphin) is a constituent of the fruit of the false indigo-bush (Amorpha fruticosa L.), which
belongs to the class of rotenoid glycosides, and shows several interesting pharmacological activities.
The aim of this study was to isolate and chemically characterize this natural product, as well as to
determine the optimal period of the year for A. fruticosa fruits collection. Fruticin was obtained by
re-crystallization of the precipitate that formed after partial evaporation of the extract, prepared by 3-
fold extraction of powdered plant material by chloroform - ethanol (1:1, v/v). The structure of the final
product was determined by various techniques of instrumental analysis (NMR, UV and MS), and con-
firmed by comparing the obtained spectra with corresponding data in available literature. The content
of fruticin in A. fruticosa fruit was determined by LC-DAD-MS, using the external standard method
based on the constructed calibration curve. Limits of detection (LOD) and quantification (LOQ) were
also determined. A substantial increase in fruticin content was observed during the ripening period
(>50 %). It has also been established that the optimal time for fruit collection is mid-December. Ob-
tained results indicate that the content of fruticin in the A. fruticosa fruit is highly dependable on the
time of collection. Since the biosynthesis of secondary plant metabolites is influenced not only by the
time of collection, but by numerous other factors as well, additional studies are needed to define, with
greater certainty, the conditions that are necessary for design of prospective efficient and sustainable
production process.
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1. INTRODUCTION
Amorpha fruticosa L. (Fabaceae), also known as false indigo-
bush or desert false indigo, is a shrub autochthonous to North
America. It was first introduced in Europe by the beginning
of the 18th century as a horticultural plant esteemed for its
ornamental qualities, as well as a melliferous species. Due
to its strong and well-developed root system, A. fruticosa has
been planted as a protection against erosion and along the
railroads to firm up the railway embankments (Krpan et al.,
2011). A. fruticosa blooms in late spring till early summer. In
early autumn, A. fruticosa bears fruit regularly and abundantly.
Its fruits are small (up to 1 cm long) warty pods, containing
one seed each. In addition to generative reproduction, it also
propagates by vegetative multiplication through rootstock
shoots. It is best suited to neutral, slightly acidic or alkaline,
moist soils and grows near water, along the river banks, where
from it spreads by water (seed pods are buoyant), especially
during floods (Krpan et al., 2011).
Thanks to specific biological properties and ability to easily
adapt and invade disturbed ecosystems of lowland floodplain
forests, pastures, meadows or vacant soils, A. fruticosa escaped
cultivation and expanded around the globe (Hulina, 2010). To-
day, it is recognized as one of the most invasive species for Eu-
rope, with serious deleterious effects on local autochthonous
lowland flora (Krpan et al., 2011). As a heliophilic plant, it
competes for the light and forms dense thickets that over-
shadow and suffocate the native flora, changing successional
patterns and reducing biodiversity (Kozuharova et al., 2017;
Krpan et al., 2011; Szigetvári, 2002). It is also widespread in
Serbia, especially in Vojvodina, Mačva, and wider Belgrade
area (Lazarević et al., 2012; Radulovic et al., 2008). Bearing in
mind the damage that this plant causes not only to floristic di-
versity and forestry, but also to water management, drainage
systems, roads etc., its presence should be reduced, or con-
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trolled by any cost. So far, the methods of biological (Gagić
et al., 2008), chemical (Blagojević et al., 2015) and mechanical
(Szigetvári, 2002) control of the distribution of this plant have
been proposed, but with certain limitations.
For that reason, some alternative approaches to the problem
of A. fruticosa control have recently emerged, with focus on
the possibilities of the employment of this plant, rather than
its eradication (Ciuvăt, et al., 2016; Kozuharova et al., 2017).
A. fruticosa has a great bio-pharmaceutical relevance, since it
is recognized as a rich source of bioactive compounds with a
high diversity of pharmacological activities. Its constituents
are secondary metabolites of different chemical nature, such
as stilbenoids (amorfrutins), flavonoids and their derivatives,
including the subgroups of flavanones, isoflavones, rotenoids,
as well as terpenoids (Kozuharova et al., 2017; López Díaz,
2016; Muharini, 2016). These constituents exhibit different ac-
tivities and mechanisms of action, including PPARα/γ agonist
effect, cytotoxicity, inhibition of TNF-α and NF-κB, antimicro-
bial (antiviral, antibacterial and antifungal) activity, etc. Wide
spectrum of pharmacological activities make this plant stand
out due to its potential application in the treatment of different
pathologies, such as diabetes mellitus, some types of cancer, as
well as various infections (Kozuharova et al., 2017; López Díaz,
2016; Muharini, 2016).
In other terms, if recognized as an inexpensive source of
pharmacologically active compounds for pharmaceutical and
related industries, this harmful weed could be eventually
brought under the sustainable control. In this context, the
aim of this paper is to present the results of investigations on
isolation and chemical characterization of fruticin (amorphin),
a rotenoid glycoside known as the most abundant constituent
of A. fruticosa fruits, in an attempt to better understand its
pharmacological values.
2. MATERIALS AND METHODS
2.1. Plant material
The plant material (fruits, in different stages of maturity) was
collected in the Autumn 2019, from a meadow at Kumodraž
(southern suburbs of Belgrade). Sample 1 (500 g) was collected
in September 2019 and used for the extraction of fruticin. Sam-
ples 2-7 (approximately 100 g per sample) were collected in
14-days intervals starting from the beginning of September
2019 and used for the quantification of fruticin. Each sample
has been dried at the room temperature, for 7 days. Identifica-
tion of the plant was performed in the Department of Botany,
Faculty of Pharmacy, Belgrade where a voucher specimen was
deposited (No. 4206HFF).
2.2. Isolation of fruticin
Ground and sifted pods of A. fruticosa (100,2 g) were extracted
as described by Khodzhaev et al. (1982) by 3-fold digestion
with the mixture of chloroform-ethanol (1:1, v/v) for 5,5 h,
4 h and 2,5 h. Combined extracts were reduced by vacuum
evaporation to approximately 1/10 of the starting volume and
left aside overnight. Resulting precipitate was separated off
using a suction filter, suspended three times in chloroform (the
solvent being removed by suction each time) and the product
was well dried in vacuo. Finally, it was re-crystallized, first
from boiling water, then from ethanol, dried and accurately
weighed.
2.3. Chemical characterization
NMR spectra (1H, 400 MHz; 13C, 101 MHz) were recorded
on Bruker AscendTM 400 instrument. Prior to analysis, the
sample of fruticin was dissolved in deuterated dimethyl sul-
foxide (DMSO-d6). Chemical shifts (σ) were expressed as
ppm, and coupling constant (J) in Hz. As internal standard,
tetramethylsilane was used (σ = 0 ppm). UV and mass spectra
of fruticin were obtained using Agilent 1260 Infinity liquid
chromatograph, equipped with a diode array and a single
quadrupole mass detectors, after a chromatographic separa-
tion as described in the section 2.4.3.
2.4. LC-DAD-MS analysis
2.4.1. Construction of calibration curve and determination of the
limits of detection and quantification
A quantity of 5.1 mg of fruticin was accurately weighed and
dissolved in LC-MS grade methanol with the aid of ultrasoni-
cation. The resulting solution was transferred to a volumetric
flask (5 mL) and made up to the marking. The prepared stock
solution (1.02 mg/mL) was used to make a series of dilutions
whose concentrations ranged between 10.2 and 680 µg/mL.
The limit of detection (LOD) and limit of quantification (LOQ)
were determined. LOD is the lowest concentration of analyte
in a sample that can be detected, while LOQ could be defined
as the lowest concentration of analyte in a sample that can be
determined with acceptable precision and accuracy. LOD and
LOQ were determined by calculating the standard response
deviation (Sd) and the slope of the calibration curve (a) using
following expressions (Malenović and Stojanović, 2010):
LOD = 3.3× Sd
a
LOQ = 10× Sd
a
2.4.2. Preparation of extracts
The extracts for fruticin assay were prepared essentially as
described by Genkina et al. (1971). In brief, approximately
1 g of powdered herbal substance was weighed accurately,
macerated 24 h with methanol (25 mL) and further shaken for
4 h at the room temperature. Prior to LC-DAD-MS analysis,
the extract was filtered and quantitatively transferred into a
volumetric flask. Each extract was prepared in triplicate.
2.4.3. Fruticin assay
Chromatographic separation was performed on reverse-phase
analytical column Zorbax SB-Aq (3.0×150 mm, stationary
phase particle size 3.5 µm), at 25 °C and mobile phase flow
rate of 0.35 mL/min ((injection volume: 3 µL; phase A - 0.1 %
solution of formic acid in water; phase B - acetonitrile). The
mobile phase gradient was programmed as follows: 25 % B
(0 min), 90 % B (30 min), 90 % B (36 min), 25 % B (38 min),
25 % B (40 min). The chromatograms were recorded at 296
nm. Mass spectra were recorded at a mass range of 100 - 1000
m/z. Electrospray ionization was performed in negative mode
under atmospheric pressure (N2 flow 10 L/min, nebulizer
pressure 40 psig, N2 temperature 350 °C, capillary voltage
3500 V; the molecular ion was obtained at a fragmentation
voltage of 100 V). Identification of fruticin in analyzed extracts
was performed by comparison of retention times (Rt) and UV
spectra of present constituents with Rt and UV spectrum of
previously isolated fruticin, which were obtained under the
same chromatographic conditions (Claisse et al., 1964). Fru-
ticin was quantified by the external standard method at 296
nm.
3. RESULTS AND DISCUSSION
The structure of fruticin was determined on the basis of good
fit of the obtained 1H and 13C NMR, UV and MS spectral data
with data from the literature and calculated molecular weight
(Crombie et al., 1975; Li et al., 1993; Liang et al., 2015; Sariaslani
and Rosazza, 1983; Wu et al., 2015). The yield of the isolated
compound was 0.14 g.
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3.1. Spectral data
1H NMR (400 MHz, DMSO-d6): σ 7.71 (1H, d, J = 7.2 Hz,
H-5), 6.68 – 6.54 (2H, m, H-4, H-7), 6.51 (1H, s, H-10), 5.47 (1H,
t, J = 7.9 Hz, H-2), 5.32 (1H, s, H-1’), 5.21 (1H, s, H-1’), 5.13 (1H,
m, H-12a), 4.52 (2H, m, H-12), 4.32 (1H, d, J = 13.2 Hz, H-3’),
4.27 – 4.06 (4H, m, H-12, H-3’, H-1”, H-1”’), 3.98 – 3.85 (2H, m,
H-6a, H-6”), 3.77 – 3.45 (9H, m, -OCH3, -OCH3, H-6”, H-4”’,
H-5”’), 3.19 – 2.90 (4H, m, H-1, H-2”, H-3”, H-4”).
13C NMR (101 MHz, DMSO-d6): σ 189.25 (C-6), 166.74 (C-
3a), 158.22 (C-13a), 149.84 (C-9), 148.06 (C-10a), 144.38 (C-2’),
143.67 (C-8), 129.67 (C-5), 113.73 (C-5a), 113.30 (C-13b), 113.03
(C-1’), 111.26 (C-7), 105.57 (C-6b), 104.91 (C-4), 103.94 (C-1”’),
102.74 (C-1”), 101.92 (C-10), 85.03 (C-2), 76.99 (C-3”), 76.20
(C-5”), 73.83 (C-2”), 73.02 (C-3”’), 72.20 (C-12a), 71.01 (C-2”’),
70.59 (C-4”), 68.51 (C-6”), 68.22 (C-3’), 67.79 (C-4”’), 66.19 (C-
12), 65.36 (C-5”’), 56.63 (-OCH3), 56.03 (-OCH3), 44.03 (C-6a),
31.27 (C-1).
UV: λmax1 = 200 nm, λmax2 = 236 nm and λmax3 = 296 nm.
ESI-MS m/z (negative mode, fragmentor voltage 100 V):
703.2 [M-H]–, 749.1 [M+HCOOH-H]–.
3.2. Fruticin content
The basic attributes of the calibration curve are given in Table
1. The content of fruticin (%) in the plant material is shown in
Table 2
Table 1. Basic attributes of the calibration curve
Artibute Value
Data points [N] 9
Concentration range [µg/mL] 10.2 - 680
Calibration equation y = 9777.2x - 4.4957
Correlation coefficient [r2] 0.9999
LOD [µg/mL] 6
LOQ [µg/mL] 19
The highest content of fruticin was determined in the sample
of A. fruticosa fruits collected in December 2019. The content
of fruticin gradually increased over time, which leads to the
conclusion that the fruit as a potential raw material for drugs
should be collected at a later stage of ripening.
Table 2. Contents of fruticin in investigated plant material








The results of presented examination are of a preliminary char-
acter. Since the synthesis of secondary metabolites can be
influenced by various external factors (e.g. soil type, altitude,
atmospheric precipitation, temperature) and plant genetics,
it is necessary to conduct more extensive studies in order to
be able to select the time suitable for A. fruticosa fruit col-
lection with greater certainty. Rotenoids are considered as
isoflavonoid derivatives that are biosynthesized by the forma-
tion of an additional oxygen ring between the B and C rings
of the isoflavone skeleton. Fruticin (Figure 1), also known as
amorphin, frutitsin, amorphigenin O-vicianoside or amorphi-
genin α-L-arabinopyranosyl-1→6-O-β-D-glucopyranoside, is
one of the most abundant constituents of A. fruticosa fruit and
one of the best known representatives of the whole rotenoids
family (Buckingham, 1993; Kozuharova et al., 2017).
Fig. 1. Fruticin (amorphigenin α-L-arabinopyranosyl-1→6-O-β-D-
glucopyranoside)
Based on this constituent, the drug Fruticin® (50 mg) was de-
veloped in the USSR and used in 1960s and 1970s as a sedative
for neurotic conditions of various origins (cardiac neurosis,
vegetative-vascular dystonia, paroxysmal neurogenic tachy-
cardia). During the use of this drug, no contraindications and
side effects were observed (Anonymous, 1968; 1974; Moiseev
and Ustinova, 1967; Syropyatov and Dzeruzhinskaya, 2001)).
Eventually, due to the emergence of novel and, presumably,
more effective synthetic drugs, Fruticin® was excluded from
the USSR drug register in 1982 as obsolete (Anonymous, 1982).
Although retracted from the drug register, pharmacological
investigations on fruticin have been continued, as the re-
sults of experimental in vitro and in vivo studies indicated
its significant medical potential. Fruticin showed an in-
hibitory effect on rat heart phosphodiesterase. Its activity
was found to be greater than the inhibitory activity of potent
flavonoids such as luteolin, kaempferol, quercetin (Petkov
et al., 1983). Hypercoagulability in rabbits with experimen-
tally induced atherosclerosis was inhibited by oral adminis-
tration of fruticin (Aı̆zikov et al., 1984). Administered at a
dose of 5 mg/kg/day, it showed a hepatoprotective effect in
rats when carbon tetrachloride/D-galactosamine was used
as toxic agents (Kloutek et al., 1985). Fruticin prevented the
development of experimental atherosclerosis in the presence
of the combination of risk factors in rabbits. It reduced the
level of cholesterol and lipoproteins that have atherogenic
potential after administration of an oral dose of 10 mg/kg
body weight in a model of hyperlipemic rats. In addition, it
hindered the development of morphological manifestations of
aortic atherosclerosis (Kurmukov et al., 1986). The cytotoxic
effect of fruticin was assessed in vitro on malignant breast
(MCF-7) and colon (HCT-116) cancer cell lines using the MTT
assay. The results showed that fruticin exhibited selective anti-
proliferative activity against the MCF-7 cell line (IC50 = 0.95
µM/mL), even better than the positive control, cisplatin (IC50
= 7.07 µM/mL). These results indicate that fruticin could be
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an important raw material for the production of anticancer
drugs (Wu et al., 2015).
We believe that the medicinal potentials of fruticin have not
been exhausted and that the use of this molecule should be
re-evaluated by means of contemporary tests in the light of
modern knowledge in physiological sciences.
CONCLUSION
Our results suggest that A. fruticosa fruits, as potential raw ma-
terial for industrial extraction of fruticin, should be collected
during the dormant phase of the plant, in late autumn or in
winter. The methodology of fruticin isolation shows promising
potentials for scale-up and use in industrial or semi-industrial
environment, with satisfactory purity of obtained product. LC-
DAD-MS or HPLC-UV/DAD could be suitable as analytical
techniques for quality control assurance. Further research on
fruticin pharmacology is needed and already in progress.
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